07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Cardiotrophin-1 regulatory update

FDA and the European Commission granted Orphan Drug designation for Digna's cardiotrophin-1 to treat acute liver failure. The recombinant human CT-1 is in Phase I testing to treat ischemic and reperfusion injuries associated with liver...
07:00 , Aug 25, 2011 |  BC Innovations  |  Cover Story

Cardiotrophin workout

A team at the University of Navarra...
07:00 , Aug 25, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Metabolic disease Obesity; metabolic syndrome Cardiotrophin-1 (CT-1) Studies in mice suggest recombinant CT-1 could help treat obesity. In wild-type mice, recombinant CT-1 increased fat utilization and...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

Cardiotrophin-1: Phase I start

Next quarter, Digna and Biotecnol will start a dose-escalation, Spanish Phase I trial to evaluate 0.3-180 µg/kg doses of IV CT-1 in 33 healthy volunteers. The partners are developing CT-1 under an amended 2007 deal...
07:00 , Sep 14, 2009 |  BC Week In Review  |  Company News

Biotecnol S.A., Digna Biotech, Roche deal

Biotecnol and partner Digna received exclusive rights to Roche's Genentech Inc. unit's patents covering cardiotrophin-1 (CT-1) proteins for use in certain liver indications. Genentech will receive an undisclosed payment and has an exclusive option to...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Biotecnol, Digna Biotech preclinical data

In rabbit models of fulminant hepatitis, CT-1 improved survival rates vs. control at 36 hours post-infection (100% vs. 55%) and at 60 hours post infection (80% vs. 18%). At 168 hours post-infection, 33% of rabbits...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Company News

Biotecnol, Digna Biotech deal

The companies changed Biotecnol’s 2007 license to manufacture Digna’s cardiotrophin-1 (CT-1) from non-exclusive to exclusive and added an exclusive option for Biotecnol to co-market CT-1 worldwide for organ transplantation and tissue regeneration. The protein that...
07:00 , May 12, 1997 |  BioCentury  |  Product Development

Products in development for ALS

Products in development for ALS...
08:00 , Dec 9, 1996 |  BioCentury  |  Strategy

CytoTherapeutics: The factors for growth

CytoTherapeutics Inc. solved a longstanding roadblock in its corporate development plans, signing an agreement with Genentech Inc. that gives CTII access to several growth factors for use in central nervous system diseases. A key problem...